Biotech Values

[Robert C Jonson]

If that is the case, why would they design a trial with ORR as primary endpoint, PFS as secondary endpoint with whatever assumptions they used?

I'm speculating, but I don't think when designing the trial they'd paired up Bavi with Docetaxel before, and thus may not have known how long it would take to work. I think you're too quick to dismiss their credentials and trial design, particularly if it's based on what I told you. I am purely an outside observer watching and waiting.

So my question to you, again, is, do they have any leeway on when to report end points like ORR, or is there an industry standard they have to adhere to?